Comparative Pharmacology
Head-to-head clinical analysis: MUSTARGEN versus URACIL MUSTARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUSTARGEN versus URACIL MUSTARD.
MUSTARGEN vs URACIL MUSTARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MUSTARGEN (mechlorethamine HCl) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Uracil mustard is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
IV: 0.4 mg/kg or 12 mg/m² BSA as a single dose or divided into 0.1 mg/kg/day for 4 days.
1 mg orally daily for 3 weeks, then 1 mg daily every 4 weeks, or 0.15 mg/kg orally once weekly.
None Documented
None Documented
Terminal half-life: 30-60 minutes (rapidly inactivated); clinical context: very short due to rapid hydrolysis and alkylation, necessitating rapid administration after reconstitution.
Clinical Note
moderateUracil mustard + Digoxin
"Uracil mustard may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateUracil mustard + Digitoxin
"Uracil mustard may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateUracil mustard + Deslanoside
"Uracil mustard may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateUracil mustard + Acetyldigitoxin
"Uracil mustard may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 6–8 hours in patients with normal renal function; may be prolonged with renal impairment
Renal: 50% as unchanged drug and metabolites; fecal: minor (<10%); biliary: minimal.
Primarily renal (56-80% as unchanged drug and metabolites); minor fecal (10%)
Category C
Category C
Alkylating Agent
Alkylating Agent